Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin

Trummer, Arne; Haarmeijer, B.; Werwitzke, Sonja; Wermes, C.; Ganser, Arnold; Budde, Ulrich; Tiede, Andreas

doi:10.1111/hae.12032

Cited by 8 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, these results confirm those of the study from Horstman et al on PMPs, 11 where an increase in PMPs' release was observed after 1 hour for 27% of the patients. These results are also consistent with those of Trummer et al, 30 who reported an increase in PMPs in patients with either type 1 VWD or “unspecified bleeding diathesis” after DDAVP administration. Moreover, these authors reported that VWF binds these PMPs.…”

Section: Discussionsupporting

confidence: 92%

“…22 The decrease in P-selectin expression and PAC-1 labeling could be explained by the fact that DDAVP enhances the synthesis of cyclic adenosine monophosphate (cAMP), which has an inhibitory effect on platelet functions. [30][31][32][33] Since cAMP has 18) at T0 and T1 on the left, then discriminating nonresponders (NR, n ¼ 6) and responders (R, n ¼ 7). PAC-1 was measured in a whole blood no-wash flow cytometry method.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, these authors reported that VWF binds these PMPs. 30 A hypothesis would be that DDAVP leads to platelet activation through the release of VWF multimers.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of DDAVP on Platelet Activation and Platelet-Derived Microparticle Generation

et al. 2021

View full text Add to dashboard Cite

Background The way by which 1-deamino-8-D-arginine vasopressin (DDAVP) acts on platelets remains unclear. Data from the literature tend to show that there is no definite effect on platelet activation, but recent work has suggested that a subtype of platelets, activated by the combined action of collagen and thrombin, was triggered by DDAVP. Moreover, platelet microparticles (PMPs), which have been shown to be procoagulant, have rarely been studied in this context. The goal of this study was to analyze the effects of DDAVP on PMPs' release through platelet activation. Methods Fifteen out of 18 consecutive patients undergoing a therapeutic test with DDAVP were included. They were suffering from factor VIII deficiency or from von Willebrand disease. The expression of P-selectin and PAC-1 binding on platelets and the numbers of circulating PMPs were evaluated ex vivo before and after DDAVP infusion. Peripheral blood was collected on CTAD to limit artifactual platelet activation. Results DDAVP induced a significant decrease of platelet counts and volume. Only small changes of P-selectin expression and PAC-1 binding were observed. Considering PMPs, two populations of patients could be defined, respectively, with (120%, n = 6) or without (21%, n = 7) an increase of PMPs after DDAVP. The decrease in platelet counts and volume remained significant in the group of responders. Conclusion This study shows that DDAVP induces the generation/release of PMPs in some patients with factor VIII deficiency and von Willebrand disease 1 hour after DDAVP infusion.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of DDAVP on Platelet Activation and Platelet-Derived Microparticle Generation

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Due to the high incidence of PPH among SSRI users (18%), desmopressin may be an attractive complement to routine treatment of women on an SSRI in order to reduce the rate of PPH and other bleeding‐related complications . Desmopressin has been shown to be effective in subjects with platelet dysfunctions , but future studies need to confirm these findings. It is also important to explore whether the bleeding‐related effects of SSRI medication is dose or concentration related.…”

Section: Discussionmentioning

confidence: 99%

Selective serotonin reuptake inhibitor use during pregnancy increases the risk of postpartum hemorrhage and anemia: a hospital‐based cohort study

Lindqvist

Nasiell

Gustafsson

et al. 2014

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

SwedenTo cite this article: Lindqvist PG, Nasiell J, Gustafsson LL, Nordstrom L. Selective serotonin reuptake inhibitor use during pregnancy increases the risk of postpartum hemorrhage and anemia: a hospital-based cohort study. J Thromb Haemost 2014; 12: 1986-92.Summary. Background: Selective serotonin reuptake inhibitors (SSRIs) are known to increase the risk of gastrointestinal bleeding. Objective: Study the risk of bleeding-related complications in relation to SSRI in pregnancy. Patients/ Methods: This was a hospital-based cohort study. All women who gave birth at Karolinska University Hospital in Stockholm over a 5-year period (2007 to 2011) were included in the study. Those women who the electronic maternal health record indicated were using SSRI (n = 500) were considered exposed, and all other women formed a control population (n = 39 594). The main outcome measures were blood loss, postpartum hemorrhage (PPH), PP anemia and length of hospitalization. Results: The absolute risk of PPH and PP anemia for the 1.2% exposed to SSRI were 18.0% and 12.8%, respectively. Women with a vaginal non-surgical delivery who reported use of SSRI during pregnancy had approximately a 2-fold increased risk of both PPH (OR, 2.6; 95% CI, 2.0-3.5) and PP anemia (OR, 2.1; 95% CI, 1.5-2.9), as compared with controls. Blood loss and length of hospitalization were significantly higher among women using SSRI than non-users (arithmetic mean 484 mL vs. 398 mL, 3.8 days vs. 2.4 days, respectively). Conclusion: The use of SSRI during pregnancy increases blood loss and doubles the risk of PPH and PP anemia in a setting where SSRI had not been considered a risk factor for increased blood loss.Because PPH is a leading cause of maternal mortality and morbidity, the awareness of bleeding-related complications is important, both in relation to pregnancy and to surgery in general.

show abstract

“…DDAVP promotes hemostasis by increasing endogenous levels of VWF and FVIII [77], and by increasing platelet activation [78]. The number of PMPs and VWF-bound MPs increases significantly after DDAVP administration [79], in conjunction with increased VWF functional activity in plasma. Furthermore, depletion of MPs from plasma significantly decreases the VWF functional activity observed after DDAVP administration.…”

Section: Phenotypic Vs Functional Assays For Microparticle Analysismentioning

confidence: 99%

Microparticle analysis in disorders of hemostasis and thrombosis

2015

View full text Add to dashboard Cite

Microparticles (MPs) are submicron vesicles released from the plasma membrane of eukaryotic cells in response to activation or apoptosis. MPs are known to be involved in numerous biologic processes, including inflammation, the immune response, cancer metastasis, and angiogenesis. Their earliest recognized and most widely accepted role, however, is the ability to promote and support the process of blood coagulation. Consequently, there is ongoing interest in studying MPs in disorders of hemostasis and thrombosis. Both phosphatidylserine (PS) exposure and the presence of tissue factor (TF) in the MP membrane may account for their procoagulant properties, and elevated numbers of MPs in plasma have been reported in numerous prothrombotic conditions. To date, however, there are few data on true causality linking MPs to the genesis of thrombosis. A variety of methodologies have been employed to characterize and quantify MPs, although detection is challenging due to their submicron size. Flow cytometry (FCM) remains the most frequently utilized strategy for MP detection; however, it is associated with significant technological limitations. Additionally, pre-analytical and analytical variables can influence the detection of MPs by FCM, rendering data interpretation difficult. Lack of methodologic standardization in MP analysis by FCM confounds the issue further, although efforts are currently underway to address this limitation. Moving forward, it will be important to address these technical challenges as a scientific community if we are to better understand the role that MPs play in disorders of hemostasis and thrombosis.

show abstract

Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin

Cited by 8 publications

References 25 publications

Effect of DDAVP on Platelet Activation and Platelet-Derived Microparticle Generation

Effect of DDAVP on Platelet Activation and Platelet-Derived Microparticle Generation

Selective serotonin reuptake inhibitor use during pregnancy increases the risk of postpartum hemorrhage and anemia: a hospital‐based cohort study

Microparticle analysis in disorders of hemostasis and thrombosis

Contact Info

Product

Resources

About